PharmiWeb.com - Global Pharma News & Resources
17-Oct-2018

Spherix Provides Video Demonstration of CBM Drug Reversing Paralysis in Preclinical Study

Spherix Provides Video Demonstration of CBM Drug Reversing Paralysis in Preclinical Study

PR Newswire

NEW YORK, Oct. 17, 2018

NEW YORK, Oct. 17, 2018 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today provided shareholders with a video demonstration on its website of the potential effectiveness of CBM BioPharma, Inc.'s ("CBM) innovative drug platform.   As previously disclosed on October 11, 2018, Spherix entered into a merger agreement with CBM, a privately held innovative pharmaceutical company focused on the development of drugs in the multibillion-dollar oncology therapeutics market.  The notable video, which was recorded at Wake Forest University, visually demonstrates the potential effectiveness of one of CBM's primary drug candidates known as KPC34.  Researchers at Wake Forest have been testing whether KPC34 can be used on mouse subjects to treat Acute Lymphoblastic Leukemia (ALL) that has spread to the nervous system.  Once recurrent ALL spreads to the nervous system, patients often experience paralysis.

 

In the video, a mouse which suffers from hind leg paralysis as a result of recurrent late staged ALL is shown to improve dramatically from the paralysis within forty-eight hours of being treated with KPC34.  Within just twenty-four hours of the first injection of KPC34, the mouse could walk. Forty-eight hours later a second injection was administered and the mouse was able to move about without challenges.

Anthony Hayes, CEO of Spherix, stated, "This remarkable video demonstrates the tremendous potential for this drug to treat ALL.  The video was part of a written submission on KPC34 to PLOS OneTM a peer reviewed medical journal. We are collecting additional information to continually provide our shareholders with updates to help better educate them on these compounds and the biotechnology space generally. We anticipate further updates in the future."

About Spherix

Spherix is committed to advancing innovation by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. Spherix has acquired over 100 patents from Rockstar Consortium Inc., and several hundred patents issued to Harris Corporation, covering a variety of methods and components involved in switching, routing, networking, optical and telecommunication sectors.

About CBM BioPharma, Inc.

CBM BioPharma, Inc. (www.cbmbiopharmainc.com) is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas at Austin.  The Company has a team of leading drug development scientists who help advance their technology.  The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and pancreatic cancer.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:


Investor Relations: 

Hayden IR


Brett Maas, Managing Partner


Phone: (646) 536-7331


Email: brett@haydenir.com


www.haydenir.com



Spherix: 

Phone: 212-745-1373


Email: investorrelations@spherix.com


www.spherix.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-provides-video-demonstration-of-cbm-drug-reversing-paralysis-in-preclinical-study-300732544.html

SOURCE Spherix Incorporated

Editor Details

Last Updated: 17-Oct-2018